Stoke Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $36,555 | $8,780 |
| Operating expenses: | ||
| Research and development | 89,133 | 82,231 |
| General and administrative | 48,794 | 41,322 |
| Total operating expenses | 137,927 | 123,553 |
| Loss from operations | (101,372) | (114,773) |
| Other income (expense): | ||
| Interest income (expense), net | 12,638 | 9,908 |
| Other income (expense), net | (247) | 166 |
| Total other income (expense) | 12,391 | 10,074 |
| Net loss | $(88,981) | $(104,699) |
| Net loss per share—basic and diluted | $(1.65) | $(2.38) |
| Weighted average common shares outstanding—basic and diluted | 54,008,883 | 43,994,862 |
| Comprehensive loss: | ||
| Net loss | $(88,981) | $(104,699) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities | (127) | 1,151 |
| Total other comprehensive gain (loss) | $(127) | $1,151 |
| Comprehensive loss | $(89,108) | $(103,548) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.